Appendix 1
Case
Sex
Age
Vaspin (ng/ml) Vaspin(ng/ml)
(before)
(After)
Treatment
1
M
28
481.1
628.7
PSL30mg, TAC 6mg
2
F
56
87.2
106.6
PSL 5mg, TAC 5mg
3
F
40
182.7
878.7
PSL 20mg, AZA 50mg, LCAP
4
M
66
201.7
653.1
AZA 25mg, TAC 8mg
5
M
48
3.2
519.0
PSL 30mg, AZA 50mg,
6
M
41
1062.5
1344.1
AZA 75mg, CyA 120mg
7
M
44
398.8
835
PSL50mg
8
F
46
55.2
70.5
AZA50mg, IFX 5mg/Kg
9
F
61
61.4
439.1
PSL 2.5mg, CyA 150mg
10
F
51
376.8
567.3
AZA75mg, TAC 6mg
11
F
46
486
941.3
AZA50mg, TAC 6mg
PSL: prednisolone TAC: tacrolimus AZA: azathioprine CyA: cyclosporin A
IFX: infliximab LCAP: leukocytapheresis
Appendix 2
P = N.S
(pg/mL)
P = N.S
(pg/mL)
P = N.S
1400
1200
1000
800
600
400
200
0
0.0
1.0
2.0
3.0
Proctitis Left-sided Extensive
n=8
n = 14
n = 11
P = N.S
1600
Serum Vaspin Concentration
Serum Vaspin Concentration
1600
P = N.S
4.0
P = N.S
1400
1200
1000
800
600
400
200
0
0.0
0.5
1.0
1.5
2.0
Chronic relapsingcontinuous remitting
n=2
n = 28
2.5
Singleattack
3.0
3.5
n=3
* Kruskal-Wallis test

Distrito Escolar Cambrian Local Control Accountability Plan Survey

View - LCAP Watch

English Language Advisory Committee (ELAC) Meeting